ANI Has Four-Pillar Growth Strategy Following Novitium Deal

As Company Sees Q4 Revenue Increase On The Back Of Generics Sales

With a four-pillar growth strategy, ANI Pharma plans over 25 product launches in 2021 and 2022. With the recent acquisition of Novitium the company is also advancing three 505(b)(2) candidates in oncology and hypertension, after seeing a slight growth in overall revenues and generics sales in 2020. 

four pillars
ANI Pharma announces a four-pillar growth strategy along with Q4 2020 results • Source: Shutterstock

A fresh four-pillar strategy for sustainable future growth has been set out by ANI Pharmaceuticals, Inc. recently-installed president, CEO and director Nikhil Lalwani, following a “gap analysis” conducted by external consultants.

Lalwani – the former Cipla US chief who took over leadership of ANI in September last year Also see "

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business